Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis

Completed · Phase 4

Conditions studied: Acute Kidney Failure

In brief

Critically ill patients in the intensive care unit often receive continuous hemodialysis to treat their kidney failure. Ertapenem is an antibiotic often used in these patients. Continuous dialysis may remove ertapenem, putting patients at risk for inappropriate treatment of their infection. This study will determine how much ertapenem is removed by continuous hemodialysis.

Key facts

Study ID

NCT00877370

Run by

University of Michigan

People needed

8

Starts

2009-02-01

Expected to finish

2011-03-01

Last updated by the study team

2012-09-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hospitalized in ICU
• Receiving Continuous hemodialysis
• Prescribed ertapenem
• Informed consent granted

You may not qualify if…

• < 18 years of age
• Allergy to ertapenem or other carbapenem antibiotic
• Severe, life-threatening reaction to penicillin or cephalosporins
• Patients experiencing or with history of CNS disorders (eg: seizure, stroke)
• Patients experiencing CNS infection
• Inability to complete 24 hours of CVVHD
• Concurrent use of other extracorporeal therapies such as extracorporeal membrane oxygenation, plasmapheresis or intermittent hemodialysis
• Inability to obtain informed consent
• Pregnant and/or breastfeeding women

Where it is running

• University of Michigan University Hospital — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.